Neuroendocrinology
Neuroendocrinology
What Do You Need to Know?
- Hypothalamic-pituitary axis — hypothalamus releases hormones into the portal system → anterior pituitary; posterior pituitary stores ADH (supraoptic nucleus) and oxytocin (paraventricular nucleus)
- Hypothalamic hormones — TRH, CRH, GnRH, GHRH, somatostatin, dopamine (prolactin-inhibiting factor); dopamine is the only major inhibitory hypothalamic hormone besides somatostatin
- Diabetes insipidus — central (low ADH) vs nephrogenic (ADH resistance); differentiate by desmopressin response
- SIADH — euvolemic hyponatremia with low serum osmolality, high urine osmolality, high urine Na+; common causes include CNS lesions, small cell lung cancer, and drugs (carbamazepine, SSRIs)
- Pituitary adenomas — prolactinoma is most common; macroadenomas compress optic chiasm → bitemporal hemianopia; treat prolactinomas medically (cabergoline), others surgically
- Neurological endocrine disorders — Hashimoto encephalopathy, myxedema coma, thyrotoxic periodic paralysis, Addisonian crisis, pheochromocytoma
- Paraneoplastic endocrine syndromes — ectopic ACTH and SIADH (small cell lung cancer), anti-NMDAR encephalitis (ovarian teratoma), limbic encephalitis
Hypothalamic-Pituitary Axis Overview
Functional Anatomy
- Hypothalamus — produces releasing and inhibiting hormones that regulate the anterior pituitary
- Hypothalamic-hypophyseal portal system — capillary network that carries hypothalamic hormones directly to anterior pituitary; bypasses systemic circulation
- Anterior pituitary (adenohypophysis) — derived from Rathke's pouch (oral ectoderm); synthesizes its own hormones under hypothalamic control
- Posterior pituitary (neurohypophysis) — derived from neural ectoderm; does NOT synthesize hormones; stores and releases ADH and oxytocin made in hypothalamic nuclei
- Pituitary stalk — connects hypothalamus to pituitary; stalk transection → loss of all anterior pituitary hormones EXCEPT prolactin (which increases due to loss of dopamine inhibition)
Key Hypothalamic Nuclei
| Nucleus | Hormone Produced | Key Function |
|---|---|---|
| Supraoptic nucleus | ADH (vasopressin) | Water balance; transported to posterior pituitary |
| Paraventricular nucleus | Oxytocin (+ some ADH); CRH | Milk letdown, uterine contractions; stress response |
| Arcuate nucleus | GnRH, GHRH, dopamine | Reproduction, growth, prolactin inhibition |
| Suprachiasmatic nucleus | N/A (pacemaker) | Circadian rhythm; receives direct retinal input |
| Ventromedial nucleus | N/A | Satiety center; lesion → hyperphagia/obesity |
| Lateral hypothalamus | Orexin/hypocretin | Hunger, arousal; loss → narcolepsy type 1 |
| Anterior hypothalamus | N/A | Cooling (parasympathetic); lesion → hyperthermia |
| Posterior hypothalamus | N/A | Heating (sympathetic); lesion → poikilothermia |
Board Pearl
Pituitary stalk transection causes deficiency of all anterior pituitary hormones EXCEPT prolactin, which RISES. Prolactin is the only anterior pituitary hormone under tonic inhibitory control (by dopamine). Loss of dopamine → hyperprolactinemia.
Hypothalamic Hormones
Releasing and Inhibiting Hormones
| Hypothalamic Hormone | Target Cell | Pituitary Hormone Affected | Effect |
|---|---|---|---|
| TRH (thyrotropin-releasing hormone) | Thyrotrophs | TSH (and prolactin) | Stimulates TSH and prolactin release |
| CRH (corticotropin-releasing hormone) | Corticotrophs | ACTH | Stimulates ACTH release; key stress hormone |
| GnRH (gonadotropin-releasing hormone) | Gonadotrophs | FSH, LH | Pulsatile → stimulates; continuous → suppresses (leuprolide mechanism) |
| GHRH (growth hormone-releasing hormone) | Somatotrophs | GH | Stimulates GH release |
| Somatostatin (GHIH) | Somatotrophs, thyrotrophs | GH, TSH | Inhibits GH and TSH release |
| Dopamine (prolactin-inhibiting factor) | Lactotrophs | Prolactin | Tonically inhibits prolactin release |
- GnRH pulsatility is critical — pulsatile release stimulates FSH/LH; continuous GnRH (or GnRH agonists like leuprolide) desensitizes receptors → suppresses gonadotropins
- TRH stimulates both TSH and prolactin — this explains why primary hypothyroidism (↑ TRH) can cause mild hyperprolactinemia
Clinical Pearl
When evaluating hyperprolactinemia, always check thyroid function. Primary hypothyroidism causes elevated TRH, which stimulates both TSH and prolactin — correcting hypothyroidism normalizes prolactin.
Anterior Pituitary Hormones
Hormones, Source Cells, and Clinical Correlations
| Hormone | Source Cell | Target | Function | Excess | Deficiency |
|---|---|---|---|---|---|
| ACTH | Corticotrophs | Adrenal cortex | Stimulates cortisol secretion | Cushing's disease (pituitary); hyperpigmentation | Secondary adrenal insufficiency (no hyperpigmentation) |
| TSH | Thyrotrophs | Thyroid gland | Stimulates T3/T4 synthesis | TSH-secreting adenoma (rare) → hyperthyroidism | Central hypothyroidism |
| FSH | Gonadotrophs | Ovaries/testes | Folliculogenesis; spermatogenesis | Rare (gonadotroph adenoma) | Hypogonadotropic hypogonadism |
| LH | Gonadotrophs | Ovaries/testes | Ovulation; testosterone production | Rare | Hypogonadotropic hypogonadism |
| GH | Somatotrophs (most abundant cell) | Liver (IGF-1), bone, muscle | Growth, metabolism | Gigantism (children); acromegaly (adults) | Dwarfism (children); ↓ lean mass (adults) |
| Prolactin | Lactotrophs | Breast | Milk production; inhibits GnRH | Galactorrhea, amenorrhea, infertility | Failure of lactation (Sheehan syndrome) |
Mnemonic: Anterior Pituitary Cells — "B-FLAT"
- Basophils — FSH, LH, ACTH, TSH
- Acidophils — GH, Prolactin
- ACTH is derived from POMC (proopiomelanocortin) → also produces MSH (melanocyte-stimulating hormone) — explains hyperpigmentation in ACTH excess (primary adrenal insufficiency, ectopic ACTH)
- Sheehan syndrome — postpartum pituitary necrosis due to hemorrhagic shock; lactotroph hypertrophy during pregnancy makes pituitary vulnerable; presents with failure to lactate, amenorrhea, fatigue
Board Pearl
Hyperpigmentation distinguishes primary from secondary adrenal insufficiency. Primary (Addison's) → high ACTH → high MSH (from POMC) → hyperpigmentation. Secondary (pituitary) → low ACTH → no hyperpigmentation.
Posterior Pituitary
ADH (Antidiuretic Hormone / Vasopressin)
- Synthesized in: supraoptic nucleus (primarily) and paraventricular nucleus
- Stored and released from: posterior pituitary
- Stimulus for release: ↑ serum osmolality (osmoreceptors in hypothalamus), ↓ blood volume/pressure (baroreceptors)
| Receptor | Location | Mechanism | Effect |
|---|---|---|---|
| V1 (V1a) | Vascular smooth muscle | Gq → IP3/DAG → Ca2+ | Vasoconstriction |
| V2 | Renal collecting duct | Gs → cAMP → aquaporin-2 insertion | Water reabsorption (antidiuretic effect) |
| V3 (V1b) | Anterior pituitary | Gq | Stimulates ACTH release |
Oxytocin
- Synthesized in: paraventricular nucleus (primarily)
- Functions: milk letdown (ejection reflex), uterine contractions during labor, social bonding
- Positive feedback: suckling → oxytocin release → milk ejection → continued suckling
Diabetes Insipidus
Central vs Nephrogenic DI — Comparison Table
| Feature | Central DI | Nephrogenic DI |
|---|---|---|
| Pathophysiology | ↓ ADH production/secretion | Kidney resistance to ADH |
| ADH level | Low | Normal or high |
| Common causes | Pituitary surgery, TBI, tumors (craniopharyngioma), infiltrative (sarcoidosis, Langerhans cell histiocytosis), idiopathic | Lithium (most common drug cause), hypercalcemia, hypokalemia, congenital (V2 receptor or AQP2 mutation) |
| Presentation | Polyuria (dilute urine), polydipsia, hypernatremia, high serum osmolality, low urine osmolality | |
| Water deprivation test | Urine remains dilute (fails to concentrate) | Urine remains dilute (fails to concentrate) |
| Desmopressin (DDAVP) response | Urine concentrates >50% (positive response) | No significant response |
| Treatment | Desmopressin (DDAVP) | Treat underlying cause; thiazide diuretics (paradoxical effect), amiloride (if lithium-induced), low-solute diet, NSAIDs |
Triphasic Response After Pituitary Surgery
- Phase 1 (days 1-5): DI — axonal shock, no ADH release → polyuria
- Phase 2 (days 5-10): SIADH — uncontrolled ADH release from degenerating neurons → hyponatremia
- Phase 3 (after day 10): Permanent DI (if >80% of ADH neurons destroyed) or recovery
Board Pearl
After pituitary/hypothalamic surgery, monitor sodium closely for the triphasic response. The SIADH phase (days 5-10) can cause dangerous hyponatremia if fluids are not restricted. Do not discharge patients too early without sodium monitoring.
Board Pearl
The desmopressin challenge differentiates central from nephrogenic DI. Central DI responds to desmopressin (urine concentrates >50%); nephrogenic DI does not. Lithium is the most common drug cause of nephrogenic DI.
SIADH (Syndrome of Inappropriate ADH Secretion)
Causes
| Category | Examples |
|---|---|
| CNS disorders | Stroke, SAH, meningitis, encephalitis, TBI, brain tumors |
| Pulmonary | Pneumonia, tuberculosis, positive-pressure ventilation, lung abscess |
| Drugs | Carbamazepine, oxcarbazepine, SSRIs, cyclophosphamide, vincristine, opioids, ecstasy (MDMA) |
| Malignancy | Small cell lung cancer (ectopic ADH production) |
| Other | Pain, nausea, postoperative state, HIV |
Diagnostic Criteria
- Hyponatremia — serum Na+ <135 mEq/L
- Low serum osmolality — <280 mOsm/kg
- Inappropriately high urine osmolality — >100 mOsm/kg (urine should be dilute in hypo-osmolar state)
- High urine sodium — >40 mEq/L
- Euvolemic (clinically)
- Normal thyroid and adrenal function (must exclude hypothyroidism and cortisol deficiency)
Treatment
- Mild/chronic: fluid restriction (first-line), salt tablets
- Moderate: demeclocycline (induces nephrogenic DI), vaptans (tolvaptan — V2 receptor antagonist)
- Severe/symptomatic (seizures, obtundation): hypertonic saline (3% NaCl)
- Correction rate: Na+ should not rise >8-10 mEq/L in 24 hours to avoid osmotic demyelination syndrome (ODS)
Board Pearl
Rapid correction of chronic hyponatremia causes osmotic demyelination syndrome (central pontine myelinolysis). Presents with quadriplegia, pseudobulbar palsy, and locked-in syndrome days after overcorrection. Maximum correction: 8-10 mEq/L per 24 hours.
Clinical Pearl
Carbamazepine and oxcarbazepine are the most important neurological drug causes of SIADH. Oxcarbazepine has a higher incidence of hyponatremia than carbamazepine. Always check sodium when initiating these antiepileptic drugs, especially in elderly patients.
Pituitary Adenomas
Classification
| Feature | Microadenoma | Macroadenoma |
|---|---|---|
| Size | <10 mm | ≥10 mm |
| Mass effect | Usually none | Optic chiasm compression, cavernous sinus invasion, headache |
| Visual field defect | Rare | Bitemporal hemianopia (superior → inferior progression) |
| Hypopituitarism | Rare | Common (compression of normal pituitary tissue) |
Functional Adenomas — Comparison
| Adenoma Type | Frequency | Clinical Features | Diagnosis | Treatment |
|---|---|---|---|---|
| Prolactinoma | Most common (~40%) | Galactorrhea, amenorrhea, infertility, ↓ libido | Serum prolactin (usually >200 ng/mL in macroadenomas) | Dopamine agonists (cabergoline, bromocriptine) — medical first-line, NOT surgery |
| GH-secreting | ~15-20% | Acromegaly (adults): coarsened features, large hands/feet, macroglossia, carpal tunnel; Gigantism (children) | IGF-1 (screening), oral glucose suppression test (GH fails to suppress) | Transsphenoidal surgery; octreotide (somatostatin analog); pegvisomant (GH receptor antagonist) |
| ACTH-secreting | ~10-15% | Cushing's disease: central obesity, moon facies, striae, proximal myopathy, HTN, DM | 24-hr urine cortisol, dexamethasone suppression test, inferior petrosal sinus sampling | Transsphenoidal surgery |
| Non-functioning | ~25-30% | Mass effect only: headache, visual field defect, hypopituitarism | MRI; negative hormonal workup | Transsphenoidal surgery if symptomatic; observation if incidental |
| TSH-secreting | Rare (<1%) | Hyperthyroidism with inappropriately normal/elevated TSH | Elevated T4 with non-suppressed TSH | Transsphenoidal surgery; octreotide |
Visual Field Defect
- Optic chiasm compression → bitemporal hemianopia (nasal retinal fibers cross at chiasm)
- Superior extension of pituitary macroadenoma compresses chiasm from below
- Typically starts with superior temporal quadrants (inferior chiasmal fibers affected first)
- Formal visual field testing (Humphrey perimetry) is essential in all macroadenomas
"Stalk Effect" vs True Prolactinoma
- Stalk effect: any large sellar mass compresses the pituitary stalk → loss of dopamine inhibition → mild prolactin elevation (usually <100-150 ng/mL)
- True prolactinoma: prolactin level usually correlates with tumor size; macroadenoma prolactin typically >200 ng/mL
- If large sellar mass + prolactin only mildly elevated → likely non-functioning adenoma with stalk effect, NOT a prolactinoma — treat surgically, not with dopamine agonist
Board Pearl
Prolactinoma is the ONLY pituitary adenoma treated medically first-line. Dopamine agonists (cabergoline) both reduce prolactin AND shrink the tumor. All other pituitary adenomas requiring treatment are managed with transsphenoidal surgery as first-line.
Neurological Endocrine Disorders
Hashimoto Encephalopathy (Steroid-Responsive Encephalopathy Associated with Autoimmune Thyroiditis — SREAT)
- Highly elevated anti-TPO antibodies (anti-thyroid peroxidase); anti-thyroglobulin may also be positive
- Thyroid function may be normal, hypo-, or hyperthyroid — encephalopathy does NOT correlate with thyroid function
- Presentation: subacute encephalopathy with confusion, cognitive decline, seizures, myoclonus, stroke-like episodes, tremor
- Diagnosis of exclusion: elevated anti-TPO + encephalopathy + no other cause identified
- Key feature: dramatic response to corticosteroids (hence "steroid-responsive")
- CSF: may show elevated protein, mild pleocytosis
Myxedema Coma
- Severe hypothyroidism → altered mental status, hypothermia, bradycardia, hypotension, hypoventilation, hyponatremia
- Often precipitated by infection, surgery, cold exposure, or sedatives
- Treatment: IV levothyroxine (T4) + IV liothyronine (T3); IV hydrocortisone (must treat concurrent adrenal insufficiency before thyroid hormone to prevent Addisonian crisis)
Thyrotoxic Periodic Paralysis
- Episodic hypokalemic paralysis in the setting of hyperthyroidism
- More common in Asian males
- Precipitants: high-carbohydrate meals, exercise, stress
- Mechanism: thyroid hormone potentiates Na+/K+-ATPase activity → intracellular K+ shift
- Treatment: correct hyperthyroidism (definitive); cautious K+ replacement (total body K+ is normal); avoid IV glucose and insulin
Addisonian Crisis
- Acute adrenal insufficiency — life-threatening
- Presentation: hypotension/shock, abdominal pain, fever, altered mental status, hyponatremia, hyperkalemia
- Precipitants: abrupt steroid withdrawal, infection, surgery, adrenal hemorrhage (Waterhouse-Friderichsen syndrome in meningococcemia)
- Treatment: IV hydrocortisone (100 mg bolus then 50 mg q8h), aggressive IV fluids, treat precipitant
- Neurological relevance: always give hydrocortisone BEFORE levothyroxine in panhypopituitarism (thyroid hormone increases cortisol metabolism → precipitates crisis)
Pheochromocytoma
- Catecholamine-secreting tumor of the adrenal medulla (or extra-adrenal paragangliomas)
- Classic triad: episodic headache + sweating + palpitations (with hypertension)
- Rule of 10s: 10% bilateral, 10% extra-adrenal, 10% malignant, 10% familial
- Associated syndromes: MEN 2A/2B, Von Hippel-Lindau, NF1, SDH mutations
- Diagnosis: plasma-free metanephrines or 24-hr urine metanephrines/VMA
- Treatment: alpha-blockade FIRST (phenoxybenzamine), then beta-blockade, then surgery
Board Pearl
Never give beta-blockers before alpha-blockade in pheochromocytoma. Unopposed alpha stimulation causes severe hypertensive crisis. Always start with phenoxybenzamine (irreversible alpha blocker) or phentolamine, then add beta-blockade.
Clinical Pearl
In panhypopituitarism, always replace cortisol BEFORE thyroid hormone. Levothyroxine increases cortisol metabolism, and administering it to a cortisol-deficient patient can precipitate an Addisonian crisis.
Paraneoplastic Endocrine Syndromes
Key Paraneoplastic Endocrine Associations
| Syndrome | Associated Tumor | Mechanism | Key Features |
|---|---|---|---|
| Ectopic ACTH | Small cell lung cancer, bronchial carcinoid, thymoma | Tumor secretes ACTH → cortisol excess | Cushing's syndrome + hypokalemic metabolic alkalosis + hyperpigmentation; high-dose dexamethasone does NOT suppress |
| Ectopic ADH (SIADH) | Small cell lung cancer | Tumor secretes ADH | Euvolemic hyponatremia; treat underlying tumor + fluid restriction |
| Anti-NMDAR encephalitis | Ovarian teratoma | Antibodies against NR1 subunit of NMDA receptor | Young woman; psychiatric symptoms → seizures → orofacial dyskinesias → autonomic instability → decreased consciousness |
| Limbic encephalitis | Small cell lung cancer (anti-Hu), testicular seminoma (anti-Ma2), thymoma (anti-CASPR2) | Antibodies targeting limbic structures | Subacute memory loss, seizures, psychiatric symptoms; MRI shows mesial temporal T2/FLAIR signal |
| Hypercalcemia (PTHrP) | Squamous cell lung cancer, renal cell, breast | Tumor secretes PTH-related peptide | Altered mental status, confusion, lethargy → coma; "stones, bones, groans, psychiatric moans" |
Differentiating ACTH Sources
| Test | Pituitary Cushing's (Cushing's Disease) | Ectopic ACTH | Adrenal Tumor |
|---|---|---|---|
| ACTH level | High (ACTH-dependent) | Very high (ACTH-dependent) | Low (ACTH-independent) |
| High-dose dexamethasone | Suppresses cortisol (>50%) | Does NOT suppress | Does NOT suppress |
| CRH stimulation | ACTH rises | No ACTH rise | No ACTH rise |
| Inferior petrosal sinus sampling | Central:peripheral ACTH ratio >2 (or >3 after CRH) | Ratio <2 | N/A |
Board Pearl
Small cell lung cancer is the most common cause of both ectopic ACTH production and ectopic ADH (SIADH). If a patient with known SCLC presents with hyponatremia, think SIADH. If they present with hypokalemia, metabolic alkalosis, and Cushingoid features, think ectopic ACTH.
Quick Reference
Neuroendocrinology Summary Table
| Condition | Key Finding | Diagnosis | Treatment |
|---|---|---|---|
| Central DI | Polyuria, hypernatremia, low ADH | Water deprivation test + desmopressin response | Desmopressin (DDAVP) |
| Nephrogenic DI | Polyuria, hypernatremia, high ADH | No response to desmopressin | Thiazides, amiloride, low-solute diet |
| SIADH | Euvolemic hyponatremia, ↑ urine osm, ↑ urine Na+ | Diagnosis of exclusion; check thyroid/adrenal | Fluid restriction; vaptans; hypertonic saline if severe |
| Prolactinoma | Galactorrhea, amenorrhea | Prolactin level; MRI pituitary | Cabergoline (medical first-line) |
| Acromegaly | Coarsened features, large hands/feet | IGF-1; oral glucose suppression test | Transsphenoidal surgery; octreotide |
| Cushing's disease | Central obesity, striae, proximal weakness | Dexamethasone suppression; IPSS | Transsphenoidal surgery |
| Hashimoto encephalopathy | Encephalopathy + high anti-TPO | Elevated anti-TPO; exclusion of other causes | Corticosteroids (dramatic response) |
| Myxedema coma | AMS + hypothermia + bradycardia | Very low T4, high TSH | IV T4 + T3; IV hydrocortisone first |
| Osmotic demyelination | Quadriplegia, locked-in state | MRI: central pontine T2 signal (delayed) | Prevention: correct Na+ ≤8-10 mEq/L per 24 hrs |
| Pheochromocytoma | Headache, sweating, palpitations triad | Plasma-free metanephrines | Alpha-blockade first, then beta, then surgery |
Board Cheat Sheet — One-Liners
- ADH made in: supraoptic nucleus; oxytocin made in: paraventricular nucleus
- Stalk transection: all anterior pituitary hormones decrease EXCEPT prolactin (increases)
- Prolactinoma: only pituitary adenoma treated medically first-line (cabergoline)
- Bitemporal hemianopia: optic chiasm compression by pituitary macroadenoma
- Stalk effect: mild prolactin elevation (<100-150) from any large sellar mass — not a prolactinoma
- Central DI responds to desmopressin; nephrogenic DI does not
- Lithium: most common drug cause of nephrogenic DI
- Carbamazepine/oxcarbazepine: most common neurological drug cause of SIADH
- ODS (central pontine myelinolysis): from overcorrection of chronic hyponatremia; max 8-10 mEq/L per 24 hrs
- Ectopic ACTH + ectopic ADH: both most commonly from small cell lung cancer
- Pheochromocytoma: alpha-block BEFORE beta-block
- Hashimoto encephalopathy: high anti-TPO + encephalopathy + steroid-responsive
- Panhypopituitarism: replace cortisol BEFORE thyroid hormone
References
- Bhatt A. Ultimate Review for the Neurology Boards. 3rd ed. Demos Medical; 2016. Chapters 1 & 10: Neuroendocrinology and Systemic Disease.
- Ropper AH, Samuels MA, Klein JP, Prasad S. Adams and Victor's Principles of Neurology. 12th ed. McGraw-Hill; 2023. Chapter 27: The Hypothalamus and Neuroendocrine Disorders.
- Melmed S, et al. Williams Textbook of Endocrinology. 14th ed. Elsevier; 2020.
- Aminoff MJ, Josephson SA. Aminoff's Neurology and General Medicine. 6th ed. Academic Press; 2021. Part II: Endocrine Diseases.
- Blumenfeld H. Neuroanatomy Through Clinical Cases. 3rd ed. Sinauer Associates; 2021.